Recent years have highlighted significant progress in understanding the underlying genetic
and epigenetic signatures of acute myeloid leukemia (AML). Most importantly, novel …

The leukemias have long served as model diseases for cancer biology and treatment. The
ability to repeatedly and safely sample malignant cells in peripheral blood and bone marrow …

Chemotherapy resistance is the main impediment in the treatment of acute myeloid
leukaemia (AML). Despite rapid advances, the various mechanisms inducing resistance …

Background Anthracycline combined with cytarabine has been the standard for induction
therapy of newly diagnosed acute myeloid leukaemia (AML) for several decades. Due to …

Objective Evaluate safety/tolerability/efficacy of MK-8242 in subjects with refractory/recurrent
AML. Methods MK-8242 was dosed po QD (30–250 mg) or BID (120–250 mg) for 7on/7off in …

Background: Even though acute myeloid leukemia (AML) occurs most commonly in adults≥
60 years, the treatment of AML in older patients remains a significant challenge. Methods …

Objective: To ascertain the efficacy and safety of daunorubicin combined with cytarabine
comparing with idarubicin combined with cytarabine as a standard induction therapy for …

Despite recent advances in chemotherapy against acute myeloid leukaemia (AML), the
disease still has high mortality, particularly for patients who tolerate extensive chemotherapy …

For decades, an induction chemotherapy combining daunorubicin with cytarabine, the so-
called '3+ 7', has remained the standard of care for younger adult patients with AML. 1 …

Previous meta‐analyses suggested that acute myeloid leukaemia induction regimens
containing idarubicin (IDA) or high‐dose daunorubicin (HDD) induce higher rates of …